TED Stock Overview
TerrAscend Corp. cultivates, processes, and sells medical and adult use cannabis in Canada and the United States. More details
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 1/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
TerrAscend Corp. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CA$0.75 |
52 Week High | CA$2.10 |
52 Week Low | CA$0.62 |
Beta | 1.89 |
11 Month Change | -33.63% |
3 Month Change | -42.75% |
1 Year Change | -48.45% |
33 Year Change | -86.73% |
5 Year Change | -66.81% |
Change since IPO | 17.00% |
Recent News & Updates
Recent updates
Shareholder Returns
TED | DE Pharmaceuticals | DE Market | |
---|---|---|---|
7D | 13.6% | -7.0% | -0.4% |
1Y | -48.5% | -21.6% | 7.1% |
Return vs Industry: TED underperformed the German Pharmaceuticals industry which returned -22.4% over the past year.
Return vs Market: TED underperformed the German Market which returned 7.8% over the past year.
Price Volatility
TED volatility | |
---|---|
TED Average Weekly Movement | 15.1% |
Pharmaceuticals Industry Average Movement | 6.9% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 11.0% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: TED's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: TED's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2017 | 1,055 | Ziad Ghanem | www.terrascend.com |
TerrAscend Corp. cultivates, processes, and sells medical and adult use cannabis in Canada and the United States. The company produces and distributes hemp-derived wellness products to retail locations; and manufactures vaporizables, concentrates, topicals, tinctures and edibles. It also operates retail dispensaries under the Apothecarium and State Flower brand names.
TerrAscend Corp. Fundamentals Summary
TED fundamental statistics | |
---|---|
Market cap | €277.66m |
Earnings (TTM) | -€87.78m |
Revenue (TTM) | €302.56m |
0.7x
P/S Ratio-2.5x
P/E RatioIs TED overvalued?
See Fair Value and valuation analysisEarnings & Revenue
TED income statement (TTM) | |
---|---|
Revenue | US$318.89m |
Cost of Revenue | US$164.49m |
Gross Profit | US$154.40m |
Other Expenses | US$246.92m |
Earnings | -US$92.52m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.32 |
Gross Margin | 48.42% |
Net Profit Margin | -29.01% |
Debt/Equity Ratio | 96.0% |
How did TED perform over the long term?
See historical performance and comparison